Cullinan Associates’s Synopsys SNPS Stock Holding History

Cullinan Associates’s Portfolio SNPS Stock Details SNPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-600	Closed	-$221K	–	245
2021 Q4	$221K	Buy	+600	New	+$202K	0.01%	223

Other funds holding SNPS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cullinan Associates's SNPS Position: Q1 2022 in Review

Cullinan Associates sold out of Synopsys (SNPS) in Q1 2022, closing a stake of 600 shares — an estimated $221K sold.

Cullinan Associates first reported a position in SNPS in Q4 2021 and held it in 1 quarter. The position peaked at $221K in Q4 2021. 833 funds tracked by Wall St. Rank hold SNPS as of Q1 2022.

Cullinan Associates reported no remaining Synopsys position as of Q1 2022 after selling out during the quarter.
Cullinan Associates sold 600 Synopsys shares in Q1 2022, an estimated $221K.
Cullinan Associates first reported a position in Synopsys in Q4 2021 and held it in 1 quarter.
Cullinan Associates's Synopsys position peaked at $221K in Q4 2021.
833 funds tracked by Wall St. Rank held Synopsys as of Q1 2022.

Based on Cullinan Associates's 13F filing for Q1 2022, filed 21 Apr 2022.